Looks like you’re on the UK site. Choose another location to see content specific to your location
ALK reports strong growth during second quarter of 2016
ALK has achieved considerable year-on-year growth in revenues during the second quarter of 2016, according to the firm's latest financial report.
The company generated a revenue total of 773 million Danish kroner (89.31 million pounds) during the quarter, representing a year-on-year organic growth rate of 41 percent. European sales of its sublingual immunotherapy tablets doubled during the period.
Sales benefited from the temporary suspension of production at ALK's main competitor, resulting in a surge in new orders from France and other markets, while an accelerated shift in favour of registered products was also observed.
Its Grazax brand saw a strong performance during Q2, while the gradual rollout of its new product Acarizax continued to be successful, with regulatory approvals for the therapy still being secured in key territories.
Total full-year revenue is now projected to exceed 2.9 billion kroner, representing a year-on-year organic growth rate of around 20 percent in terms of its base business operations.
The company stated: "The markets in Europe have not yet normalised following a temporary halt in production by ALK's main competitor, and ALK expects to have a clearer view on the sustained impact on its market share gains during autumn."
With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard